Allergy Therapeutics (LON:AGY)‘s stock had its “corporate” rating reissued by investment analysts at FinnCap in a report issued on Monday. They presently have a GBX 47 ($0.65) price target on the stock. FinnCap’s target price indicates a potential upside of 80.77% from the company’s previous close.

Separately, Numis Securities reiterated a “buy” rating and set a GBX 45 ($0.62) price target on shares of Allergy Therapeutics in a research report on Wednesday, January 31st.

Allergy Therapeutics (LON:AGY) opened at GBX 26 ($0.36) on Monday. Allergy Therapeutics has a 12-month low of GBX 23 ($0.32) and a 12-month high of GBX 39.50 ($0.55).

COPYRIGHT VIOLATION WARNING: “Allergy Therapeutics (AGY) Rating Reiterated by FinnCap” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at

Allergy Therapeutics Company Profile

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with's FREE daily email newsletter.